DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill Annual Summer Seminar. The conference is being held at the Boston Marriott Long Wharf Hotel. James E. Brown, DVM, President and Chief Executive Officer, will be presenting at the conference on Wednesday, August 3^rd at 9:00 a.m. Eastern Time.

There will be a live webcast of the presentation from the conference. The webcast will be available on DURECT's website under the Event Calendar section of ‘Investor Relations’. The presentation will also be available for replay on DURECT's website for a period of up to 30 days after the conference.

ABOUT DURECT

DURECT Corporation is an emerging specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies that treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the SABER™ Delivery System (a patented and versatile depot injectable useful for protein and small molecule delivery), the ORADUR™ sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the DURIN™ Biodegradable Implant (drug-loaded implant system), the TRANSDUR™ transdermal technology and the MICRODUR™ Biodegradable Microparticulates (microspheres injectable system). DURECT also collaborates with pharmaceutical companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DURECT has five disclosed on-going development programs of which four are in collaboration with pharmaceutical partners. Additional information about DURECT is available at www.durect.com.

NOTE: SABER™, ORADUR™, DURIN™, TRANSDUR™ and MICRODUR™ are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.

DURECT Corporation:

Schond L. Greenway, Executive Director, IR and Strategic Planning,

+1-408-777-1417.

Return to PR archive